Classification

The following table outlines the features of Partial (Focal) Epilepsy, classified according to the International League Against Epilepsy (ILAE) 2017 guidelines (with previous terminology in parentheses).

ClassificationEtiologyClinical FeaturesSemiology (Signs & Symptoms)EEG Features
Focal Aware Seizures
(Formerly: Simple Partial Seizures)
Structural: Cortical dysplasia, tumor, vascular malformation, post-stroke gliosis.
Genetic: KCNQ2/3 mutations (Benign Familial Neonatal).
Infectious: Cysticercosis, tuberculoma.
Metabolic: Hypocalcemia, hypoglycemia.
Consciousness: Preserved (Fully aware of self/environment).
Duration: Seconds to minutes.
Post-ictal: Usually no confusion; immediate return to baseline.
Motor: Clonic jerking (Jacksonian march), tonic posturing, version (head turning).
Sensory: Paresthesias, visual flashes, auditory buzzing.
Autonomic: Epigastric rising, sweating, flushing, ictal tachycardia.
Psychic: Déjà vu, fear, forced thinking.
Interictal: Focal sharp waves or spikes over the affected region (e.g., temporal or frontal leads).
Ictal: Rhythmic focal discharge; Note: Surface EEG may be normal in deep/small foci (e.g., frontal lobe).
Focal Impaired Awareness Seizures
(Formerly: Complex Partial Seizures)
Mesial Temporal Sclerosis: Most common cause in temporal lobe epilepsy.
Limbic System Pathology: Tumors (DNET), gliosis.
Infectious: Herpes encephalitis sequelae.
Consciousness: Impaired (Staring, unresponsiveness).
Duration: 1–2 minutes.
Aura: Often preceded by a focal aware seizure (aura).
Post-ictal: Confusion, fatigue, amnesia for event, transient aphasia (if dominant hemisphere).
Automatisms:
Oro-alimentary: Lip smacking, chewing, swallowing.
Manual: Fumbling, picking at clothes.
Ambulatory: Wandering.
Motor: Dystonic posturing (contralateral limb).
Interictal: Anterior temporal spikes/sharp waves (temporal lobe); midline/frontal spikes (frontal lobe).
Ictal: Rhythmic theta (4–7 Hz) or delta activity, typically evolving in amplitude and frequency.
Focal to Bilateral Tonic-Clonic Seizures
(Formerly: Secondarily Generalized)
Progression: spread of discharge from a focal focus to bilateral networks (corpus callosum/thalamocortical).Consciousness: Initially preserved (aura) then lost.
Evolution: Focal onset Generalization.
Post-ictal: Deep sleep, Todd’s paresis (transient focal weakness).
Onset: Asymmetrical tonic posturing (Figure of 4).
Progression: Bilateral symmetric tonic stiffening followed by rhythmic clonic jerking.
Onset: Focal spikes or sharp waves.
Progression: Rapid generalization to high-amplitude polyspikes and slow waves obscuring focal onset.

Treatment of Simple Partial Seizures (Focal Aware Seizures)

1. General Management Principles

  • Goal: Complete seizure freedom with no adverse effects.
  • Diagnosis Confirmation: Ensure the event is epileptic and not a mimic (e.g., TIA, migraine, psychogenic).
  • Initiation: Pharmacotherapy is usually started after the second unprovoked seizure. Treatment after a single seizure is considered if there is a high risk of recurrence (abnormal EEG/MRI, structural lesion).

2. Pharmacotherapy (First-Line Agents)

  • Carbamazepine (CBZ): Long-standing first-line agent. Effective for focal seizures.
    • Dose: Start 10–20 mg/kg/day. Monitor for rash (HLA-B*1502 screening in risk populations) and hyponatremia.
  • Oxcarbazepine (OXC): Similar efficacy to CBZ with fewer side effects and no auto-induction of metabolism.
    • Dose: 8–10 mg/kg/day starting.
  • Levetiracetam (LEV): increasingly preferred due to broad spectrum, rapid titration, and lack of drug interactions.
    • Dose: 10–60 mg/kg/day.
  • Lamotrigine (LTG): Effective and well-tolerated but requires slow titration to avoid Stevens-Johnson Syndrome.
    • Usage: Often preferred in women of childbearing age.

3. Alternative and Add-On Therapies

  • Second-Line/Adjunctive: Lacosamide, Topiramate, Zonisamide, Valproate.
  • Topiramate: Good for comorbidities like migraine or obesity.
  • Lacosamide: Sodium channel blocker, available IV/PO, useful for rapid loading.

4. Management of Refractory Cases

  • Definition: Failure of two appropriately chosen and tolerated AED schedules.
  • Surgical Evaluation: If a structural lesion (e.g., tumor, dysplasia) is identified, resection (lesionectomy) may be curative.
  • Neurostimulation: Vagus Nerve Stimulation (VNS) or Responsive Neurostimulation (RNS) for non-surgical candidates.

5. Lifestyle and Education

  • Avoid Precipitating Factors: Sleep deprivation, alcohol, stress.
  • Safety: Precautions regarding driving, swimming, and heights.

Management of Complex Partial Seizures (Focal Impaired Awareness Seizures)

1. Definition and Goals

  • Current Terminology: Classified as Focal Impaired Awareness Seizures (ILAE 2017).
  • Goal: Complete seizure freedom with minimal medication side effects (QoL preservation).
  • Strategy: Accurate diagnosis Monotherapy Polytherapy Surgical evaluation if refractory.

2. Acute Management (Seizure First Aid)

  • Most events are self-limiting (1–2 mins).
  • Immediate Care:
    • Ensure safety: Remove dangerous objects, place in lateral decubitus position (recovery position) to prevent aspiration.
    • Do Not: Restrain the patient or insert objects into the mouth.
    • Observation: Note time of onset, automatisms (lip-smacking, wandering), and post-ictal lateralizing signs (e.g., nose wiping, Todd’s palsy).
  • Rescue Medication: If seizure lasts >5 minutes (Status Epilepticus protocol):
    • Midazolam: 0.2 mg/kg Intranasal/Buccal/IM.
    • Lorazepam: 0.1 mg/kg IV.

3. Diagnostic Evaluation for Management Planning

  • Video EEG: Essential to correlate semiology with electrographic onset (localize focus). Standard EEG detects interictal spikes (anterior temporal/frontal).
  • MRI Brain (Epilepsy Protocol): Mandatory to rule out structural lesions.
    • Common substrates: Mesial Temporal Sclerosis (MTS), Focal Cortical Dysplasia (FCD), Low-grade tumors (DNET, Ganglioglioma).

4. Pharmacologic Management (Long-term)

Principles: Start low, go slow. Monotherapy is successful in 50–70% of patients.

  • First-Line Agents (Drugs of Choice):

    • Carbamazepine (CBZ): Gold standard for focal seizures.
      • Dose: 10–20 mg/kg/day (Start 5 mg/kg, titrate biweekly).
      • Monitor: CBC (agranulocytosis), Sodium (hyponatremia), HLA-B*1502 (SJS risk).
    • Oxcarbazepine (OXC): Similar efficacy to CBZ, better tolerability, less enzyme induction.
      • Dose: 8–10 mg/kg/day initially.
    • Levetiracetam (LEV): Increasing first-line usage due to safety profile, no drug interactions, and rapid titration.
      • Dose: 20–60 mg/kg/day.
  • Second-Line / Adjunctive Agents:

    • Lamotrigine (LTG): Excellent for focal epilepsy; requires slow titration (risk of rash). Preferred in women of childbearing age.
    • Topiramate (TPM): Broad spectrum; caution for cognitive slowing/weight loss.
    • Lacosamide (LCM): Sodium channel blocker; low interaction profile.
    • Valproate (VPA): Broad spectrum; useful if generalized seizure overlap is suspected or diagnosis is unclear.

5. Management of Drug-Resistant (Refractory) Epilepsy

  • Definition: Failure of 2 tolerated, appropriately chosen AED schedules (monotherapy or combination).
  • Pre-Surgical Evaluation: ~30% of focal epilepsy becomes refractory.
    • Video-EEG telemetry, High-resolution MRI (3T), PET/SPECT scans.
  • Surgical Options (Curative):
    • Anterior Temporal Lobectomy: Standard of care for Mesial Temporal Sclerosis (MTS). 60–80% seizure freedom rate (higher than medication alone).
    • Lesionectomy: For discrete tumors or dysplasia.
  • Palliative Procedures (Non-resective):
    • Vagus Nerve Stimulation (VNS): For non-surgical candidates.
    • Responsive Neurostimulation (RNS): Closed-loop stimulation for seizure abortion.
    • Ketogenic Diet: Adjunct in children with refractory epilepsy.